Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation
Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, Guillaume Coll · 2024
Read Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation by Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, Guillaume Coll (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11642482.txt.
Description
Melina Screnci and co-authors review a drug for ear nerve tumors in a genetic disease in this 2024 paper. In neurofibromatosis type 2, benign tumors grow on the hearing nerve on both sides, threatening hearing and balance. Surgery and radiation work but risk nerve damage, so a gentler drug option is attractive.
The review pooled nine studies with 176 patients treated with bevacizumab, an antibody that blocks blood vessel growth signals. Tumors shrank by at least a fifth in 40 percent of cases and stayed stable in half. Hearing improved in 36 percent and held steady in 46 percent. Severe side effects, including high blood pressure, were noted. The authors weigh the drug's promise against its risks.
Catalog record
| CREATOR | Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, Guillaume Coll |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |